Incretin Mechanisms of Action Explained

Summary

Incretin-based weight-loss drugs act on a small number of hormone receptors with distinct physiological jobs. Understanding which receptor does what explains why dual and triple agonists outperform single-receptor drugs, and why side-effect profiles differ. This page is a mechanism reference, not a treatment guide.

Last reviewed 2026-09-01

What it is

Incretins are gut hormones released after eating that amplify insulin secretion. The two principal human incretins are GLP-1 and GIP. Modern weight-management pharmacology extends beyond incretins proper to include glucagon and amylin receptor agonism.

The incretin effect — the observation that oral glucose provokes far more insulin than intravenous glucose — was described in the 1960s. GLP-1 was characterised in the 1980s, and the first GLP-1 receptor agonist reached the market in 2005.

All four target hormones are endogenous: GLP-1 and GIP from the gut, glucagon from pancreatic alpha cells, amylin from beta cells.

Each receptor contributes a different physiological lever, so combining them produces effects that no single-receptor agent achieves.

How it works

In plain terms

Four different hormone signals are in play. Two reduce appetite, one increases how much energy the body burns, and one makes meals feel satisfying earlier. Newer drugs pull several of these levers at once.

Technical detail

GLP-1R agonism acts on POMC/CART neurons in the hypothalamic arcuate nucleus and on the area postrema, reduces energy intake and delays gastric emptying, and enhances glucose-dependent insulin secretion. GIPR agonism adds an insulinotropic effect, improves adipose tissue lipid buffering and appears to attenuate nausea via central GIPR signalling. GCGR agonism increases hepatic fatty acid oxidation and total energy expenditure — the only lever in the set that acts on the expenditure side of the balance. Amylin receptor agonism engages hindbrain satiety circuits separate from GLP-1 and may improve leptin sensitivity. Effect size scales with how many complementary levers a molecule engages, not simply with potency at any one receptor.

Pathways involved

GLP-1R — appetite suppression and gastric emptying
GIPR — insulinotropic effect, adipose handling, nausea attenuation
GCGR — energy expenditure and hepatic fat oxidation
AMY receptors — hindbrain satiety, leptin sensitivity

Current research

Laboratory research

Receptor-specific knockouts and selective agonist/antagonist studies established which effects belong to which receptor.

Animal research

Comparative rodent studies at matched exposure consistently show additive weight effects as receptors are added, with the glucagon component contributing measurable energy expenditure increases.

Human research

Head-to-head trials mirror the preclinical hierarchy: single GLP-1 agonism produced roughly 15% mean weight reduction in STEP-1, dual GIP/GLP-1 agonism about 21% in SURMOUNT-1, and triple agonism about 24% in the retatrutide Phase 2. These are separate trials with different populations and durations, so cross-trial comparison is indicative rather than definitive.

Ongoing research

Selective GIP antagonism, oral small-molecule GLP-1 agonists and muscle-preserving co-therapies are the main frontiers.

What is being investigated

Which receptor contributes which share of weight effect
Whether GIP agonism or antagonism is superior long term
Energy expenditure contribution of glucagon receptor activity
Preservation of lean mass during rapid weight loss
Non-metabolic effects of GLP-1 receptors in brain, heart and kidney

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Cross-trial comparisons overstate differences; populations, durations and escalation schedules vary
Mechanistic elegance does not guarantee outcome benefit — several plausible combinations have failed in trials
Gastrointestinal effects scale with GLP-1 activity and are the principal tolerability limit
Energy expenditure effects from glucagon agonism come with heart rate and glycaemic considerations
None of this constitutes guidance on use; all of these agents require clinical supervision where they are approved at all

Evidence ratings

Laboratory studies

Strong

Receptor attribution firmly established.

Animal studies

Strong

Consistent additive-effect hierarchy.

Human studies

Strong

Multiple large trials, though few direct head-to-head.

Long-term safety

Moderate

Strongest for GLP-1, absent for triple agonism.

References

[1]Incretin physiology reviews — PubMed, 2010–present
[2]Multi-receptor agonist pharmacology — PubMed, 2020–present
[3]Glucagon receptor agonism and energy expenditure — PubMed, 2015–present
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is the incretin effect?+

The observation that oral glucose triggers substantially more insulin secretion than the same glucose given intravenously, because gut hormones amplify the response.

What is the difference between GLP-1 and GIP?+

Both are gut incretins, but GLP-1 dominates appetite and gastric emptying effects while GIP contributes insulinotropic action and adipose tissue lipid handling.

Why add glucagon to a weight-loss drug?+

Glucagon receptor activation increases energy expenditure and hepatic fat oxidation, adding an output-side mechanism to appetite-side drugs.

Does glucagon not raise blood sugar?+

Alone, yes. In combined agonists the incretin components increase glucose-dependent insulin secretion, which offsets it at the ratios used.

Which mechanism causes nausea?+

GLP-1 receptor activation, principally through the area postrema. GIP activity may partially attenuate it.

How does amylin differ from GLP-1?+

Amylin signals satiety through hindbrain circuits that are partly separate from GLP-1's, which is why combining them is additive.

Do more receptors always mean more weight loss?+

The trend so far points that way, but effect also depends on ratio, dose and tolerability. Several combinations have failed despite mechanistic promise.

Why is muscle loss a mechanistic issue?+

These drugs reduce total energy intake substantially, and rapid weight loss from any cause reduces lean mass unless protein intake and resistance training offset it.

Continue your research

Retatrutide research

Tirzepatide research

Metabolic health